Floatz logo

Adriamycin

Angioimmunoblastic T-Cell Lymphoma

City of Hope Medical CenterSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

51 Active assets in the Angioimmunoblastic T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Isocyclophosphamide
Shandong Provincial Hospital
Phase 4BBB
Dexasone
Ou Bai, MD/PHD
Phase 2BB
Azacitidine
National Cancer Institute (NCI)
Phase 4BB
Prednisone
Shanghai Jiao Tong University School of Medicine
Phase 4BB
Romidepsin
The Lymphoma Academic Research Organisation
Phase 3BB

View all 50 →

Same molecule, other indications

Adriamycin is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
77 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
76 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →